DNA of cancer cell

The term "DNA of cancer cell" refers broadly to the genetic material within a malignant or transformed cell. This is not a specific molecular target but rather encompasses all genomic content—genes, regulatory elements, structural features—within a cancerous cell. Cancer arises when mutations accumulate in key genes controlling growth, division, apoptosis, and genome maintenance. These include oncogenes (which promote proliferation when activated), tumor suppressor genes like TP53 and RB1 (which normally inhibit uncontrolled growth), and genes involved in repairing damaged DNA[2][5][6][7]. Cancer therapies often exploit vulnerabilities created by these mutations—for example, using PARP inhibitors against tumors deficient in homologous recombination repair due to BRCA1/2 loss[3]. However, "DNA" itself is not considered a canonical therapeutic target like an enzyme or receptor; rather it is the substrate affected by many drugs. The concept also lacks specificity since every human somatic cell contains essentially similar types of nuclear genomic material; what distinguishes "cancer cell DNA" are its acquired mutations and epigenetic changes that drive malignancy. Because this entry does not refer to a single protein/gene/receptor but instead generically describes all genetic material within any malignant cell type—and because it cannot be targeted directly without affecting normal cellular function—it should be flagged as incorrect for structured drug-target databases. Instead, more precise targets would be individual mutant proteins encoded by altered genes within the cancer genome. “Most cancer-causing DNA changes occur in sections called genes... As scientists have learned more about molecular changes that lead to cancer... there are now many treatments available that target gene mutations found in cancers.” [6] “It is usual for cells to repair faults in their genes... Mutations mean that a cell no longer understands instructions... The best known tumour suppressor gene is p53.” [5]

Other names

Cancer cell DNATumor DNAMalignant cell DNA

PARP inhibitors exploit synthetic lethality in cells with defective homologous recombination repair pathways[3]. DNA-damaging agents induce double-strand breaks or crosslinks that are lethal to rapidly dividing cells. Topoisomerase inhibitors prevent proper unwinding or re-ligation of the double helix during replication.